Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Denardo

Showing results (271-280 of 274) with videos related to

Pageof 28
Sort By:
You have reached the last page of results.This site can display upto 274 results.
Anticancer Research|August 26, 1998
Maximum tolerated dose of 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: a pilot studyG L Denardo, S J Denardo, D L Kukis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2001
Radioimmunotherapy with (111)In/(90)Y-2IT-BAD-m170 for metastatic prostate cancerR T O'Donnell, S J DeNardo, A Yuan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2005
High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibodyCarol M Richman, Sally J Denardo, Robert T O'Donnell, et al.
Journal of Skin Cancer|February 1, 2013
Safety and efficacy of 188-rhenium-labeled antibody to melanin in patients with metastatic melanomaM Klein, M Lotem, T Peretz, et al.
Pageof 28

Showing results (271-280 of 274) with videos related to

Sort By:
Pageof 28
You have reached the last page of results.This site can display upto 274 results.
Anticancer Research|August 26, 1998
Maximum tolerated dose of 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: a pilot studyG L Denardo, S J Denardo, D L Kukis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2001
Radioimmunotherapy with (111)In/(90)Y-2IT-BAD-m170 for metastatic prostate cancerR T O'Donnell, S J DeNardo, A Yuan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2005
High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibodyCarol M Richman, Sally J Denardo, Robert T O'Donnell, et al.
Journal of Skin Cancer|February 1, 2013
Safety and efficacy of 188-rhenium-labeled antibody to melanin in patients with metastatic melanomaM Klein, M Lotem, T Peretz, et al.
Pageof 28